Glenmark, Ichnos launch alliance to accelerate new drug discovery in cancer treatment

30 Jan 2024 Evaluate

Glenmark Pharmaceuticals and Ichnos Sciences Inc. (Ichnos), its global fully integrated, clinical?stage biotech subsidiary, have launched their alliance - Ichnos Glenmark Innovation (IGI) - to accelerate new drug discovery in cancer treatment. This alliance combines Glenmark’s research and development proficiencies in small molecules with those of Ichnos in novel biologics to continue developing cutting?edge therapy solutions that treat hematological malignancies and solid tumors.  

The newly formed IGI features a robust pipeline of three innovative oncology molecules targeting multiple myeloma, acute myeloid leukemia and solid tumors currently undergoing clinical trials. Two of these molecules have received orphan drug designation from the USFDA. Additionally, IGI has two autoimmune disease assets that have been out licensed to leading companies

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. 


Glenmark Pharma Share Price

1054.25 -17.40 (-1.62%)
30-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1502.30
Dr. Reddys Lab 6198.90
Cipla 1402.20
Zydus Lifesciences 957.00
Lupin 1645.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.